Table I.
Studies included in the systematic review according to coronavirus disease 2019 status.
| Author | Design | No. of patients | Follow-up, days | COVID-19-positive patients | Non-COVID-19 patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Deaths, n | Females, n | Mean age, yrs (SD) | Mortality, % | No. at admission | No. after admission |
Time to dx, days † | N | Deaths, n | Females, n | Mean age, yrs (SD) | Mortality, % | ||||
| Arafa 36 | RETRO | 97 | 30 | 19 | 7 | 10 | 86.2 (7.7) | 36.8 | ? | ? | ? | 78 | 7 | 57 | 83.1 (7.6) | 9 |
| Catellani 37 | RETRO | 16 | ? | 16 | 7 | 6 | 84.3 (4.4) | 43.8 | ? | ? | ? | N/A | N/A | N/A | N/A | N/A |
| Cheung 38 | RETRO | 10 | ? | 10 | 1 | 8 | 79.7 (6.7) | 10.0 | 7 | 3 | 5, 8, & 9 | N/A | N/A | N/A | N/A | N/A |
| Chui 39 | RETRO | 47 | ? | 8 | 4 | ? | ? | 50.0 | ? | ? | ? | 39 | 1 | ? | ? | 2.6 |
| Clement 7 | RETRO | 354 | 50 | 47 | 17 | ? | ? | 36.2 | 4 | 43 | ? | 307 | 50 | ? | ? | 16.3 |
| Clough 40 | RETRO | 84 | ? | 7 | 5 | 3 | 85.1 ‡ | 71.4 | 0 | 7 | ? | 77 | 13 | 49 | 80.0 ‡ | 16.9 |
| De 41 | RETRO | 276 | 30 | 34 | 14 | 22 | 85.9 (7.7) | 41.2 | ? | ? | ? | 242 | ? | ? | ? | N/A |
| Dupley 9 | RETRO | 64 | 30 | 64 | 21 | 35 | 83 (9.0) | 32.8 | 12 | 52 | ? | N/A | N/A | N/A | N/A | N/A |
| Egol 42 | PROSP | 138 | 30 | 31 | 11 | 15 | 81.6 (9.9) | 35.5 | ? | ? | ? | 107 | 6 | 73 | 83.4 (10.4) | 5.6 |
| Fadulelmola 18 | RETRO | 75 | 30 | 20 | 10 | 13 | 83.7 ‡ | 50.0 | 6 | 14 | mean 13 | 55 | 4 | 40 | 83.5 ‡ | 7.3 |
| Hall 6 | RETRO | 317 | 30 | 27 | 9 | 13 | 83.6 (11.3) | 33.3 | 6 | 21 | ? | 290 | 24 | 198 | 80.4 (10.6) | 8.3 |
| Karayiannis 19 | RETRO | 203 | 30 | 21 | 4 | ? | ? | 19.0 | ? | ? | ? | 182 | 3 | ? | ? | 1.6 |
| Kayani 20 | RETRO | 442 | 30 | 82 | 25 | 51 | 71.9 (9.5) | 30.5 | 42 | 40 | ? | 340 | 35 | 204 | 72.7 (6.7) | 10.3 |
| Lazizi 21 | RETRO | 31 | 11.5 | 3 | 2 | 1 | 88 (5.2) | 66.7 | 0 | 3 | 2, 4, & 14 | 28 | 0 | ? | ? | 0 |
| LeBrun 22 | RETRO | 59 | ? | 9 | 5 | 6 | 86.5 (7.9) | 55.6 | 7 | 2 | ? | 50 | 2 | 38 | 84.7 (7.5) | 4 |
| Macey 23 | RETRO | 76 | 30 | 10 | 2 | ? | ? | 20.0 | 1 | 9 | mean 25 | 66 | 9 | ? | ? | 13.6 |
| Malik-Tabassum 24 | RETRO | 68 | 30 | 1 | 1 | ? | ? | 100.0 | 1 | 0 | N/A | 67 | 5 | ? | ? | 7.5 |
| Maniscalco 25 | RETRO | 121 | 21 | 32 | 14 | ? | ? | 43.8 | ? | ? | ? | 89 | 3 | ? | ? | 3.4 |
| Mi 26 | RETRO | 6 | 30 * ? | 6 | 3 | 4 | 75.7 (13.0) | 50.0 | 2 | 4 | mean 7 | N/A | N/A | N/A | N/A | N/A |
| Muñoz Vives 27 | RETRO | 136 | 10 | 23 | 7 | ? | ? | 30.4 | ? | ? | ? | 113 | 6 | ? | ? | 5.3 |
| Morelli 28 | RETRO | 10 | 14 to 39 | 10 | 2 | 8 | 83.9 (7.4) | 20.0 | 10 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Muse 29 | RETRO | 5 | 8 to 15 | 5 | 0 | 4 | 79 (8.2) | 0.0 | 5 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Narang 30 | PROSP | 682 | 30 | 86 | 30 | 53 | 86 ‡ | 34.9 | ? | ? | ? | 596 | 36 | 424 | 83.0 ‡ | 6 |
| Rabie 31 | RETRO | 4 | ? | 4 | 2 | 3 | 81 (9.0) | 50.0 | 3 | 1 | ? | N/A | N/A | N/A | N/A | N/A |
| Segarra 32 | PROSP | 68 | 30 | 2 | 1 | 1 | 87.5 ‡ | 50.0 | 2 | 0 | ? | 66 | 7 | 45 | 82.2 ‡ | 10.6 |
| Sobti 33 | PROSP | 94 | ? | 6 | 3 | ? | ? | 50.0 | ? | ? | ? | 88 | 6 | ? | ? | 6.82 |
| Stoneham 34 | RETRO | 48 | ? | 1 | 0 | ? | ? | 0.0 | 0 | 1 | 20 | 47 | 0 | ? | ? | 0 |
*
Probably 30 days follow-up but not clearly stated.
†
Absolute number of days stated, unless a mean is given.
‡
No SD available.
?, not recorded; COVID-19, coronavirus disease 2019; dx, diagnosis; N/A, not applicable; PROSP, prospective; RETRO, retrospective.